-
公开(公告)号：EP0646016B1
公开(公告)日：1999-08-25
申请号：EP93916644.3
申请日：1993-06-18
Applicant: YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD.
Inventor： SELA, Michael , MOZES, Edna
IPC: A61K39/00 , A61K38/04 , C07K14/705
CPC classification number: C07K14/70571 , A61K39/00
Abstract: Peptides having at least nine amino acid residues each including an amino acid sequence which corresponds to position p200-208 or p262-266 of the human acetylcholine receptor α-subunit, but differing therefrom by one or more amino acid substitutions, are disclosed. These peptides inhibit the proliferative response of human peripheral blood lymphocytes to the myasthogenic peptides p195-212 and p259-271 and are suitable for treatment of subjects afflicted with myasthenia gravis.
-
Patent Agency Ranking2.发明公开PHARMACEUTICAL COMPOSITIONS COMPRISING SYNTHETIC PEPTIDE COPOLYMERS AND METHODS FOR PREVENTING AND TREATING GVHD AND HVGD 审中-公开药物组合物的角鲨烷为防止及治疗GVHD和HVGD的合成肽与方法
公开(公告)号：EP1128839A1
公开(公告)日：2001-09-05
申请号：EP99960378.0
申请日：1999-11-12
Applicant: YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD.
Inventor： AHARONI, Rina , TEITELBAUM, Dvora , ARNON, Ruth , SELA, Michael
IPC: A61K38/00
CPC classification number: A61L27/227 , A61K38/16 , A61L27/22
Abstract: Compositions and methods for treating and preventing host-versus-graft disease and graft-versus-host disease comprising as active ingredient random copolymers of amino acids comprising one amino acid from at least three of the following groups: (a) lysine and arginine; (b) glutamic acid and aspartic acid; (c) alanine and glycine; and (d) tyrosine and tryptophan; with the proviso that the random copolymer is not Copolymer 1 or D-Copolymer 1 when the disease being treated is graft-versus-host disease.
-
公开(公告)号：EP0646016A1
公开(公告)日：1995-04-05
申请号：EP93916644.0
申请日：1993-06-18
Applicant: YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD.
Inventor： SELA, Michael , MOZES, Edna
CPC classification number: C07K14/70571 , A61K39/00
Abstract: Peptides having at least nine amino acid residues each including an amino acid sequence which corresponds to position p200-208 or p262-266 of the human acetylcholine receptor α-subunit, but differing therefrom by one or more amino acid substitutions, are disclosed. These peptides inhibit the proliferative response of human peripheral blood lymphocytes to the myasthogenic peptides p195-212 and p259-271 and are suitable for treatment of subjects afflicted with myasthenia gravis.
Abstract translation: 公开了具有至少9个氨基酸残基的肽，每个氨基酸序列包含对应于人乙酰胆碱受体α亚基的位置p200-208或p262-266但与其有一个或多个氨基酸取代不同的氨基酸序列。 这些肽抑制人外周血淋巴细胞对产生肌肉的肽p195-212和p259-271的增殖反应，并且适用于治疗患有重症肌无力的受试者。
-
4.发明公开METHODS AND COMPOSITIONS FOR CANCER THERAPY AND FOR PROGNOSTICATING RESPONSES TO CANCER THERAPY 失效方法和用于癌症治疗的组合物和反应，这种治疗方法VORHERRAGBARKEIT。
公开(公告)号：EP0554441A1
公开(公告)日：1993-08-11
申请号：EP92918871.0
申请日：1992-08-21
Inventor： BACUS, Sarah, S. , YARDEN, Yosef , SELA, Michael
CPC classification number: G01N33/5011 , A61K38/00 , A61K47/6855 , C07K16/3015 , C07K16/32 , C07K2317/73
Abstract: Procédé de détermination de l'efficacité d'un agent thérapeutique, in vitro, utilisé dans le traitement d'un cancer caractérisé par l'expression ou la surexpression d'un produit oncogène. Le procédé est notamment utile pour déterminer l'efficacité d'agents thérapeutiques présentant une affinité de liaison pour le cancer, exprimant HER-2/neu. L'invention concerne également les anticorps monoclonaux N24, N28 et N29 identifiés par ce procédé. On peut utiliser un ou plusieurs de ces anticorps comme agent thérapeutique dans le traitement des cancers du sein, de l'estomac, des ovaires ou des glandes salivaires.
-
5.发明授权METHODS AND COMPOSITIONS FOR CANCER THERAPY AND FOR PROGNOSTICATING RESPONSES TO CANCER THERAPY 失效方法和组合物用于癌症治疗和反应的可预测性对这种治疗
公开(公告)号：EP0554441B1
公开(公告)日：1999-01-27
申请号：EP92918871.2
申请日：1992-08-21
Inventor： BACUS, Sarah, S. , YARDEN, Yosef , SELA, Michael
IPC: G01N33/50 , C07K16/32 , A61K39/395
CPC classification number: G01N33/5011 , A61K38/00 , A61K47/6855 , C07K16/3015 , C07K16/32 , C07K2317/73
Abstract: A method for determining the efficacy of a therapeutic agent, in vitro, for a cancer expressing or overexpressing an oncogene product is described. The method is particularly useful for determining the efficacy of therapeutic agents that have a binding affinity for cancer that express HER-2/neu. N24, N28 and N29 monoclonal antibodies are described which have been identified by this method. One or more of these antibodies can be used as a therapeutic agent in the treatment of breast, stomach, ovarian or salivary cancers.
-
公开(公告)号：EP2337800A1
公开(公告)日：2011-06-29
申请号：EP09787543.9
申请日：2009-08-19
Applicant: Yeda Research And Development Company Ltd.
Inventor： SELA, Michael , YARDEN, Yosef , SCHECHTER, Bilha , BEN-KASUS, Tsipi
CPC classification number: A61K39/3955 , A61K2039/505 , A61K2039/507 , C07K16/32 , C07K2317/565
Abstract: A method of identifying a combination of antibodies with a combined improved anti-tumor activity is provided. The method comprising: (a) identifying binding epitopes of anti ErbB-2 antibodies; and (b) selecting a combination of at least two antibodies of the anti ErbB-2 antibodies exhibiting binding to different epitopes on the ErbB-2, at least one of the different epitopes being localized to a dimerization site of the ErbB-2, the combination of antibodies being with the combined improved anti-tumor activity. Also provided are novel antibody combinations uncovered according to the present teachings.
-
-
-
-
-
Search Results
6
records
(took 0.028 seconds)
